Targeting USP9X-AMPK Axis in ARID1A-Deficient Hepatocellular Carcinoma
Feng-Kun Zhang,Qian-Zhi Ni,Kang Wang,Hui-Jun Cao,Dong-Xian Guan,Er-Bin Zhang,Ning Ma,Yi-Kang Wang,Qian-Wen Zheng,Sheng Xu,Bing Zhu,Tian-Wei Chen,Ji Xia,Xiao-Song Qiu,Xu-Fen Ding,Hao Jiang,Lin Qiu,Xiang Wang,Wei Chen,Shu-Qun Cheng,Dong Xie,Jing-Jing Li
DOI: https://doi.org/10.1016/j.jcmgh.2022.03.009
IF: 8.797
2022-04-01
Cellular and Molecular Gastroenterology and Hepatology
Abstract:Background & AimsHepatocellular carcinoma(HCC) is a highly heterogeneous solid tumor with high morbidity and mortality. AT-Rich Interaction Domain 1A (ARID1A) accounts for up to 10% of mutations in liver cancer, however, its role in HCC remains controversial, and no targeted therapy has been established.MethodsThe expression of ARID1A in clinical samples was examined by Western blot and immunohistochemical staining. ARID1A was knocked out by CRISPR/Cas9 in HCC cell lines, and the effects of glucose deprivation on cell viability, proliferation and apoptosis were measured. Mass spectrometry analysis was employed to find ARID1A-interacting proteins, and the result was verified by Co-immunoprecipitation and GST pull-down. Regulation of ARID1A target gene USP9X was investigated by chromatin immunoprecipitation, GST pull-down and luciferase reporter assay, etc. Finally, drug treatments were carried out to explore the therapeutic potential of the agents targeting ARID1A-deficient HCC in vitro and in vivo.ResultsOur study has revealed that ARID1A loss protected cells from glucose deprivation-induced cell death. Mechanism study disclosed that AIRD1A recruited HDAC1 via its C-terminal region DUF3518 to the promoter of USP9X, resulting in downregulation of USP9X and its target PRKAA2. ARID1A knockout and a 1989* truncation mutant in HCC abolished this effect, increased the acetylation of H3K9 and H3K27 in USP9X promoter, and upregulated the expression of USP9X and PRKAA2, which mediated the adaptation of tumor cells to glucose starvation. Compound C dramatically inhibited the growth of ARID1A-deficient tumors and prolongs the survival of tumor-bearing mice.ConclusionsHCC patients with ARID1A mutation may benefit from synthetic lethal therapy targeting USP9X/AMPK axis.
gastroenterology & hepatology